Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
Edward Kim(University of California, Davis), Karen Kelly(Cancer Research Center), Thomas J. Semrad(University of California, Davis), David R. Gandara(University of California, Davis), Karen Matsukuma(Sacramento City College), Tianhong Li(VA Northern California Health Care System), Ai‐Ming Yu(University at Buffalo, State University of New York), Jonathan W. Riess(University of California Davis Medical Center), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 4
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k